Judith PJ et al., 2024-09-16: Randomised phase II trial in 42 patients with advanced breast cancer: adding oral curcumin to docetaxel did not improve objective response (55.6% vs 73.7% with docetaxel alone, p = 0.25).
no difference was observed for the objective response rate (p = 0.25, control 73.7% vs. experimental 55.6%).
Abstract, Results
Judith PJ et al., 2024-09-16: Randomised phase II trial in 42 patients with advanced breast cancer: adding oral curcumin to docetaxel did not improve objective response (55.6% vs 73.7% with docetaxel alone, p = 0.25). Open-label, interim analysis on 37 patients. Numerical disadvantage in the curcumin arm is not statistically significant and should not be read as harm. Comparator: docetaxel alone. Study type: randomized trial.
